OncoCyte (OCX) Short Interest Ratio & Short Volume $3.07 +0.13 (+4.42%) Closing price 04:00 PM EasternExtended Trading$3.08 +0.01 (+0.16%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OncoCyte Short Interest DataOncoCyte (OCX) has a short interest of 326,700 shares, representing 1.63% of the float (the number of shares available for trading by the public). This marks a -19.01% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.1, indicating that it would take 4.1 days of the average trading volume of 57,350 shares to cover all short positions.Current Short Interest326,700 sharesPrevious Short Interest403,400 sharesChange Vs. Previous Month-19.01%Dollar Volume Sold Short$1.01 millionShort Interest Ratio4.1 Days to CoverLast Record DateApril 30, 2025Outstanding Shares28,599,000 sharesFloat Size20,060,000 sharesShort Percent of Float1.63%Today's Trading Volume26,849 sharesAverage Trading Volume57,350 sharesToday's Volume Vs. Average47% Short Selling OncoCyte? Sign up to receive the latest short interest report for OncoCyte and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartOCX Short Interest Over TimeOCX Days to Cover Over TimeOCX Percentage of Float Shorted Over Time OncoCyte Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2025326,700 shares $1.01 million -19.0%1.6%4.1 $3.08 4/15/2025403,400 shares $1.19 million +10.5%2.0%4.9 $2.94 3/31/2025365,100 shares $1.12 million -2.3%1.8%4.5 $3.06 3/15/2025373,800 shares $1.40 million +22.4%2.5%4.2 $3.74 2/28/2025305,500 shares $855,400.00 -4.4%2.1%3.1 $2.80 2/15/2025319,500 shares $817,920.00 -7.3%2.2%3.6 $2.56 1/31/2025344,600 shares $713,322.00 +7.9%2.6%3.8 $2.07 1/15/2025319,400 shares $702,680.00 -0.1%2.4%4 $2.20 12/31/2024319,700 shares $760,886.00 +6.4%2.4%4.1 $2.38 12/15/2024300,500 shares $697,160.00 +36.9%2.2%4.4 $2.32 Get the Latest News and Ratings for OCX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. 11/30/2024219,500 shares $535,580.00 -2.7%1.6%3.4 $2.44 11/15/2024225,600 shares $588,816.00 +16.2%1.6%6.5 $2.61 10/31/2024194,200 shares $588,426.00 +2.6%1.5%10.1 $3.03 10/15/2024189,300 shares $590,616.00 +5.4%1.4%9.6 $3.12 9/30/2024179,600 shares $511,860.00 -1.8%1.5%7.4 $2.85 9/15/2024182,900 shares $563,332.00 -3.8%1.5%5.8 $3.08 8/31/2024190,200 shares $597,228.00 -6.4%1.6%5.6 $3.14 8/15/2024203,100 shares $599,145.00 -10.2%1.7%5.7 $2.95 7/31/2024226,100 shares $709,954.00 -22.4%1.9%5.9 $3.14 7/15/2024291,300 shares $978,768.00 -36.4%2.5%7.3 $3.36 6/30/2024458,300 shares $1.35 million +22.3%3.9%6 $2.95 6/15/2024374,600 shares $1.03 million -2.6%3.2%5.6 $2.76 5/31/2024384,500 shares $1.05 million +10.0%3.4%6.2 $2.74 5/15/2024349,700 shares $1.01 million -6.6%3.1%5.7 $2.89 4/30/2024374,200 shares $931,758.00 +60.5%3.6%6.6 $2.49 4/15/2024233,100 shares $589,743.00 +30.2%3.1%4.2 $2.53 3/31/2024179,100 shares $524,763.00 +0.5%2.4%21.3 $2.93 3/15/2024178,300 shares $531,334.00 +0.4%2.4%13.5 $2.98 2/29/2024177,600 shares $516,816.00 -2.8%2.3%13.1 $2.91 2/15/2024182,800 shares $524,636.00 -1.5%2.4%14.3 $2.87 1/31/2024185,600 shares $575,360.00 -5.7%2.4%10.3 $3.10 1/15/2024196,800 shares $661,248.00 +8.3%2.6%10.6 $3.36 12/31/2023181,800 shares $454,500.00 -4.4%2.4%9.2 $2.50 12/15/2023190,100 shares $589,310.00 -10.4%2.5%11.7 $3.10 11/30/2023212,200 shares $806,360.00 +4.7%2.8%14.4 $3.80 11/15/2023202,600 shares $802,296.00 -1.1%2.7%13.2 $3.96 10/31/2023204,800 shares $464,896.00 +8.4%2.7%15.8 $2.27 10/15/2023188,900 shares $612,980.50 +0.9%2.5%9.9 $3.25 9/30/2023187,200 shares $584,064.00 +0.7%2.5%10 $3.12 9/15/2023185,900 shares $593,021.00 +8.3%2.5%9.4 $3.19Here’s How to Claim Your Stake in Elon’s Private Company, xAI (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos 8/31/2023171,600 shares $616,044.00 +3.5%2.3%8.2 $3.59 8/15/2023165,800 shares $553,772.00 +157.9%2.2%7.9 $3.34 7/31/202364,300 shares $268,131.00 +43.2%0.9%3.2 $4.17 7/15/202344,900 shares $195,135.40 -95.6%N/A3.5 $4.35 6/30/20231,020,000 shares $234,600.00 -4.7%N/A3.4 $0.23 6/15/20231,070,000 shares $230,050.00 -24.7%N/A3.2 $0.22 5/31/20231,420,000 shares $303,454.00 +22.4%N/A2.7 $0.21 5/15/20231,160,000 shares $308,560.00 -2.5%N/A2.3 $0.27 4/30/20231,190,000 shares $326,060.00 -14.4%N/A2.4 $0.27 4/15/20231,390,000 shares $443,688.00 +5.3%N/A2.8 $0.32 3/31/20231,320,000 shares $467,808.00 +6.5%N/A2.8 $0.35 3/15/20231,240,000 shares $248,000.00 +24.0%N/A2.7 $0.20 2/28/20231,000,000 shares $363,900.00 -4.8%N/A3.6 $0.36 2/15/20231,050,000 shares $471,975.00 -13.2%N/A3.6 $0.45 1/31/20231,210,000 shares $465,971.00 -14.2%N/A3.1 $0.39 1/15/20231,410,000 shares $688,080.00 -16.6%N/A3.4 $0.49 12/30/20221,690,000 shares $542,321.00 -14.7%N/A4.1 $0.32 12/15/20221,980,000 shares $792,000.00 -4.4%N/A5.1 $0.40 11/30/20222,070,000 shares $973,107.00 -12.7%N/A6.5 $0.47 11/15/20222,370,000 shares $967,908.00 -6.3%N/A6.1 $0.41 10/31/20222,530,000 shares $1.73 million -1.9%N/A7.9 $0.68 10/15/20222,580,000 shares $2.00 million -1.5%N/A9.1 $0.78 9/30/20222,620,000 shares $1.91 million +5.7%N/A8.8 $0.73 9/15/20222,480,000 shares $2.23 million -8.2%N/A5.6 $0.90 8/31/20222,700,000 shares $2.13 million No ChangeN/A5.5 $0.79 7/30/20213,040,000 shares $0.00 -3.8%3.6%6.9 $0.00 7/15/20213,160,000 shares $0.00 +2.6%3.6%6.9 $0.00 6/30/20213,080,000 shares $0.00 -4.6%3.6%6.2 $0.00 6/15/20213,230,000 shares $0.00 +14.1%3.8%6.4 $0.00 5/28/20212,830,000 shares $0.00 +2.9%3.3%4.5 $0.00 5/14/20212,750,000 shares $0.00 -0.4%N/A3.6 $0.00 4/30/20212,760,000 shares $0.00 +0.7%N/A2.9 $0.00 4/15/20212,740,000 shares $12.38 million +19.7%N/A2.2 $4.52 3/31/20212,290,000 shares $11.45 million +9.1%N/A1.6 $5.00 3/15/20212,100,000 shares $10.94 million +6.1%N/A1.4 $5.21 2/26/20211,980,000 shares $9.41 million +4.2%6.6%0.8 $4.75 2/12/20211,900,000 shares $7.07 million -4.5%N/A0.8 $3.72 1/29/20211,990,000 shares $11.66 million -21.3%N/A0.9 $5.86 1/15/20212,530,000 shares $14.07 million +1.2%N/A1.3 $5.56 12/31/20202,500,000 shares $6.08 million +12.6%N/A1.1 $2.43 12/15/20202,220,000 shares $4.71 million -14.3%N/A1.1 $2.12 11/30/20202,590,000 shares $4.64 million +7.5%N/A2.7 $1.79 11/15/20202,410,000 shares $4.19 million -0.8%N/A2.3 $1.74 10/30/20202,430,000 shares $3.86 million +4.3%N/A2.3 $1.59 10/15/20202,330,000 shares $4.08 million -17.1%N/A1.9 $1.75 9/30/20202,810,000 shares $3.91 million +24.9%N/A3.3 $1.39 9/15/20202,250,000 shares $3.26 million +23.6%N/A2 $1.45 8/31/20201,820,000 shares $2.28 million +8.3%N/A1.6 $1.25 8/14/20201,680,000 shares $2.94 million -5.6%N/A1.7 $1.75 7/31/20201,780,000 shares $2.40 million +2.3%N/A1.8 $1.35Buffett’s favorite chart just hit 209% – here’s what that means for gold (Ad)A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Be ready before the historic gold move. Get Garrett’s Top Four picks now. 7/15/20201,740,000 shares $2.21 million -7.0%N/A2.2 $1.27 6/30/20201,870,000 shares $6.04 million +52.0%N/A2.7 $3.23 6/15/20201,230,000 shares $2.93 million +4.2%N/A3.4 $2.38 5/29/20201,180,000 shares $3.10 million +0.9%N/A4.3 $2.63 OCX Short Interest - Frequently Asked Questions What is OncoCyte's current short interest? Short interest is the volume of OncoCyte shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 326,700 shares of OCX short. 1.63% of OncoCyte's shares are currently sold short. Learn More on OncoCyte's current short interest. What is a good short interest ratio for OncoCyte? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OCX shares currently have a short interest ratio of 4.0. Learn More on OncoCyte's short interest ratio. What is a good short interest percentage for OncoCyte? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.63% of OncoCyte's floating shares are currently sold short. Is OncoCyte's short interest increasing or decreasing? OncoCyte saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 326,700 shares, a drop of 19.0% from the previous total of 403,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is OncoCyte's float size? OncoCyte currently has issued a total of 28,599,000 shares. Some of OncoCyte's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. OncoCyte currently has a public float of 20,060,000 shares. How does OncoCyte's short interest compare to its competitors? 1.63% of OncoCyte's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to OncoCyte: Arcturus Therapeutics Holdings Inc. (21.09%), Heron Therapeutics, Inc. (21.83%), Benitec Biopharma Inc. (1.38%), Fulcrum Therapeutics, Inc. (6.30%), Atyr PHARMA INC (13.57%), Atai Life Sciences (8.95%), Aurora Cannabis Inc. (9.46%), Aquestive Therapeutics, Inc. (9.47%), Compass Therapeutics, Inc. (8.69%), DBV Technologies S.A. (0.59%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short OncoCyte stock? Short selling OCX is an investing strategy that aims to generate trading profit from OncoCyte as its price is falling. OCX shares are trading up $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against OncoCyte? A short squeeze for OncoCyte occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OCX, which in turn drives the price of the stock up even further. How often is OncoCyte's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OCX, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies ARCT Short Interest Data HRTX Short Interest Data BNTC Short Interest Data FULC Short Interest Data ATYR Short Interest Data ATAI Short Interest Data ACB Short Interest Data AQST Short Interest Data CMPX Short Interest Data DBVT Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OCX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
